DOCSLIB.ORG

Nature2017.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Nature2017.Pdf ARTICLE DOI: 10.1038/s41467-017-00992-9 OPEN Insights into beta cell regeneration for diabetes via integration of molecular landscapes in human insulinomas Huan Wang1,2,14, Aaron Bender2,3, Peng Wang3, Esra Karakose3, William B. Inabnet4, Steven K. Libutti5, Andrew Arnold6, Luca Lambertini7, Micheal Stang8, Herbert Chen9, Yumi Kasai10, Milind Mahajan1, Yayoi Kinoshita11, Gustavo Fernandez-Ranvier4, Thomas C. Becker12, Karen K. Takane 3, Laura A. Walker3, Shira Saul 3, Rong Chen1,14, Donald K. Scott3, Jorge Ferrer 13, Yevgeniy Antipin1,14, Michael Donovan11, Andrew V. Uzilov1,14, Boris Reva1, Eric E. Schadt 1,14, Bojan Losic1, Carmen Argmann1 & Andrew F. Stewart3 Although diabetes results in part from a deficiency of normal pancreatic beta cells, inducing human beta cells to regenerate is difficult. Reasoning that insulinomas hold the “genomic recipe” for beta cell expansion, we surveyed 38 human insulinomas to obtain insights into therapeutic pathways for beta cell regeneration. An integrative analysis of whole-exome and RNA-sequencing data was employed to extensively characterize the genomic and molecular landscape of insulinomas relative to normal beta cells. Here, we show at the pathway level that the majority of the insulinomas display mutations, copy number variants and/or dys- regulation of epigenetic modifying genes, most prominently in the polycomb and trithorax families. Importantly, these processes are coupled to co-expression network modules asso- ciated with cell proliferation, revealing candidates for inducing beta cell regeneration. Vali- dation of key computational predictions supports the concept that understanding the molecular complexity of insulinoma may be a valuable approach to diabetes drug discovery. 1 The Department of Genetics and Genomic Sciences and The Icahn Institute for Genomics and Multiscale Biology, The Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. 2 The Graduate School, The Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. 3 The Diabetes Obesity and Metabolism Institute, The Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. 4 The Department of Surgery, The Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. 5 The Cancer Institute of New Jersey, Rutgers University, New Brunswick, NJ 08901, USA. 6 Center for Molecular Medicine, University of Connecticut School of Medicine, Farmington, CT 06030, USA. 7 The Departments of Environmental Medicine and Public Health and Obstetrics, Gynecology, and Reproductive Sciences, The Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. 8 The Department of Surgery, Duke University School of Medicine, Durham, NC 27710, USA. 9 The Department of Surgery, University of Alabama at Birmingham, Birmingham, AL 35233, USA. 10 The New York Genome Center, New York, NY 10013, USA. 11 The Department of Pathology, The Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. 12 The Sarah W. Stedman Center for Nutrition and Metabolism, Duke University School of Medicine, Durham, NC 27710, USA. 13 The Department of Genetics in Medicine, Imperial College, London, W12 0NN, UK. 14Present address: Sema4, a Mount Sinai venture, Stamford, CT 06902, USA. Huan Wang, Aaron Bender, Peng Wang, Esra Karakose, William B. Inabnet, and Steven K. Libutti contributed equally to this work. Eric E. Schadt, Bojan Losic, Carmen Argmann, and Andrew F. Stewart jointly supervised this work. Correspondence and requests for materials should be addressed to A.F.S. (email: [email protected]) NATURE COMMUNICATIONS | 8: 767 | DOI: 10.1038/s41467-017-00992-9 | www.nature.com/naturecommunications 1 ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-00992-9 ormal physiologic human beta cell replication occurs only human beta cells. We reasoned that although some molecular transiently in human infancy and early childhood, ceasing events in insulinoma are likely relevant to the mechanisms of N 1 irreversibly thereafter . Therapeutically, there is only one tumor formation, some may serve to uncover the genetic class of drugs, still in early development, that reproducibly mechanisms that enforce beta cell quiescence, and are bypassed in induces human beta cell replication: the harmine analogue class such benign tumors. We further validated combinations of lead – of small molecules that inhibit the kinase, DYRK1A2 4. Even candidate genes derived from this approach as beta cell mitogenic here, however, the replication rates induced are modest and not mediators. Notably, we focused on insulinomas from subjects not beta cell-specific. Accordingly, there is an urgent need to discover known to be members of multiple endocrine neoplasia type 1 additional beta cell mitogenic drugs and regenerative pathways. (MEN1) kindreds, as the MEN1 gene has been previously Insulinomas are very rare, small (~ 1–2 cm), slowly proliferating reported as one of the most frequently mutated genes in her- pancreatic beta cell adenomas5, 6. They come to medical attention editary pancreatic neuroendocrine tumors (PNETs), although – through their overproduction of insulin, causing hypoglycemia, MEN1 mutations are uncommon in sporadic insulinomas5 7. with resultant psychomotor symptoms5, 6. They are almost always Despite attempting to exclude MEN1 subjects, we nevertheless benign, and are readily treated by laparoscopic removal. Since they find widespread abnormalities in genes functionally related to are a rare tumor, they are not captured in large cancer genomic MEN1, revealing a previously unsuspected unifying mechanism surveys such as The Cancer Genome Atlas (TGCA) or the underlying insulinoma. International Cancer Genome Consortium (ICGC). Here we report whole-exome sequencing (WES) and RNA sequencing (RNAseq) of thirty-eight human insulinomas. We pro- Results vide these findings for public access with extensive sets of annota- Insulinomas harbor recurrent mutations in epigenetic genes. tions relating to the DNA variants identified, with the ability to WES was performed on genomic DNA from insulinomas and prioritize selection of high-impact mutations in a user-defined way. patient-matched blood cells (as normal controls) from 22 Our primary intent was to employ an integrative genomics patients, with a mean usable sequencing depth of 79X and 105X approach to identify mitogenic mechanisms with potential for the blood and tumor samples, respectively. We included WES application for human beta cell expansion (Supplementary data from four additional insulinomas from a prior report8, Fig. 1). This approach entails integrating whole-exome and RNA- yielding a total of 26 insulinomas with paired normal and tumor sequencing data into network analysis to computationally model DNA data (Supplementary Tables 1, Supplementary Data 1). insulinoma molecular events relative to normal adult and juvenile Mutation analysis was performed as described9, 10. After manual d Structure-specific CDX2 SMARCC1 KDM6A DNA binding Adj P- value 9398T Tumor: 4418T 5408T 8003T BGI_INS38 5407T BGI_INS20 4950T 5331T 5405T 5967T BGI_INS15 5863T 4974T 5329T 5322T 5320T 5406T 5318T 5326T 5333T 5404T 6066T 4973T BGI_INS40 6107T ARHGAP35 <0.01 25 H3F3A a SNV Indel/MNV STAG2 RNF111 20 <0.005 15 10 PER2 MLH3 PSIP1 <0.0005 of SNVs/ 5 Chromatin MNVs/indels Total numbers YY1 0 binding YY1 # genes 4 MEN1 SMAD 2 H3F3A ERBB4 0–5 2 KDM6A binding 2 MEN1 CREBBP 5–10 2 ATR 2 FLNC SMURF1 10–20 2 ARHGAP35 PAX6 DRD2 Regulatory region NCAM2 KATNAL1 DNA binding LMO2 Transcriptional MYOCD CDX2 repressor activity, R-SMAD SMURF1 NDNL2 RNA Pol II activating binding STAG2 TF binding MLLT4 TMTC1 COL4A5 10–6 10–4 10–2 0.1 FDR del MICAL1 efY 1p36.33 X 1q21.3 SUFU 22 1 1q21.1 1 1 1q21.3 ADAMTS9 21 20 2q21.2 GPS1 2q21.2 3p25.3 19 2 2 SLC27A4 2 2q21.2 3q29 RNF111 18 3 3 4p16.3 IL7R 7q11.21 4 4 PIWIL2 17 5q23.1 7q22.1 5 5 7q22.1 NLRP5 3 7p21.3 6 6 9q13 SNVs and indels: Missense Splice site Nonsense Frameshift 16 7q21.12 11p15.5 7q22.1 7 7 11p11.2 CNVs: Gain Loss cnLOH 8 8 b 12 840 7q34 11p11.12 15 9 9 11q13.1 MEN1 4 10p15.1 CDKN1C 10 10 12q24.31 10p11.23 16p13.3 EZH2 14 11 11 0 12q12 16q22.1 12q12 12 12 16q24.3 5 13 13 17p13.2 1000 13 14q11.2 14 14 17p11.2 14q32.33 15 15 17q21.2 size (Mb) Total CNV 16 16 2000 17p11.2 17q25.1 12 17 17 19p13.2 Insulinomas with genomic 6 17q21.2 c 18 18 19q13.31 aberration in selected 19q13.2 19 19 19q13.33 epigenetic modifers (85%) 11 7 20q11.1 20 20 19q13.42 21 21 19q13.42 10 22 22 9 8 22q13.1 amp FDR 0.1 10–2 10–3 10–4 Fig. 1 Global molecular characterization of the insulinoma genomic landscape from whole-exome sequencing data. a A summary of 26 insulinomas (top box) and a subset of their protein-changing key driver variants, each sample displaying the variant with the highest allelic fraction and, if any, the variant from recurrently mutated genes. All variants are somatic, except for a germline MEN1 variant from sample 5967T (at chr11:64,572,613, G>A, p.R420*, nonsense). b A summary of somatic copy number variants from selected model-predicted epigenetic modifiers and CDKN1C. c A summary showing which 85% of insulinomas harbor mutations or CNVs in selected epigenetic modifiers. d GO pathway analysis (Molecular Function) of insulinoma key driver variants reveals terms associated with chromatin-binding and SMAD signaling as the most prominent pathways. e Circos plot of copy number gain (red), loss (blue), or copy-neutral cnLOH (green). Each line within a track represents 20% of the total number of insulinomas. Note that ~ 20% of insulinomas have CNV loss on chromosome 11 (blue), and ~ 20–40% have CNV gain on chromosome 7 (red). f GISTIC2.0 analysis showing finer mapping of regions of significant chromosomal amplification or deletion throughout the genome.
Load more

Recommended publications
  • Cytotoxic Effects and Changes in Gene Expression Profile
    Toxicology in Vitro 34 (2016) 309–320 Contents lists available at ScienceDirect Toxicology in Vitro journal homepage: www.elsevier.com/locate/toxinvit Fusarium mycotoxin enniatin B: Cytotoxic effects and changes in gene expression profile Martina Jonsson a,⁎,MarikaJestoib, Minna Anthoni a, Annikki Welling a, Iida Loivamaa a, Ville Hallikainen c, Matti Kankainen d, Erik Lysøe e, Pertti Koivisto a, Kimmo Peltonen a,f a Chemistry and Toxicology Research Unit, Finnish Food Safety Authority (Evira), Mustialankatu 3, FI-00790 Helsinki, Finland b Product Safety Unit, Finnish Food Safety Authority (Evira), Mustialankatu 3, FI-00790 Helsinki, c The Finnish Forest Research Institute, Rovaniemi Unit, P.O. Box 16, FI-96301 Rovaniemi, Finland d Institute for Molecular Medicine Finland (FIMM), University of Helsinki, P.O. Box 20, FI-00014, Finland e Plant Health and Biotechnology, Norwegian Institute of Bioeconomy, Høyskoleveien 7, NO -1430 Ås, Norway f Finnish Safety and Chemicals Agency (Tukes), Opastinsilta 12 B, FI-00521 Helsinki, Finland article info abstract Article history: The mycotoxin enniatin B, a cyclic hexadepsipeptide produced by the plant pathogen Fusarium,isprevalentin Received 3 December 2015 grains and grain-based products in different geographical areas. Although enniatins have not been associated Received in revised form 5 April 2016 with toxic outbreaks, they have caused toxicity in vitro in several cell lines. In this study, the cytotoxic effects Accepted 28 April 2016 of enniatin B were assessed in relation to cellular energy metabolism, cell proliferation, and the induction of ap- Available online 6 May 2016 optosis in Balb 3T3 and HepG2 cells. The mechanism of toxicity was examined by means of whole genome ex- fi Keywords: pression pro ling of exposed rat primary hepatocytes.
    [Show full text]
  • Breed Relationships Facilitate Fine-Mapping Studies: a 7.8-Kb Deletion Cosegregates with Collie Eye Anomaly Across Multiple Dog Breeds
    Downloaded from genome.cshlp.org on October 4, 2021 - Published by Cold Spring Harbor Laboratory Press Article Breed relationships facilitate fine-mapping studies: A 7.8-kb deletion cosegregates with Collie eye anomaly across multiple dog breeds Heidi G. Parker,1 Anna V. Kukekova,2 Dayna T. Akey,3 Orly Goldstein,2 Ewen F. Kirkness,4 Kathleen C. Baysac,1 Dana S. Mosher,1 Gustavo D. Aguirre,5 Gregory M. Acland,2 and Elaine A. Ostrander1,6 1Cancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland 20892, USA; 2Baker Institute for Animal Health, College of Veterinary Medicine, Cornell University, Ithaca, New York 14853, USA; 3Department of Genome Sciences, School of Medicine, University of Washington, Seattle, Washington 98195, USA; 4The Institute for Genomic Research, Rockville, Maryland 20850, USA; 5Department of Clinical Studies, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA The features of modern dog breeds that increase the ease of mapping common diseases, such as reduced heterogeneity and extensive linkage disequilibrium, may also increase the difficulty associated with fine mapping and identifying causative mutations. One way to address this problem is by combining data from multiple breeds segregating the same trait after initial linkage has been determined. The multibreed approach increases the number of potentially informative recombination events and reduces the size of the critical haplotype by taking advantage of shortened linkage disequilibrium distances found across breeds. In order to identify breeds that likely share a trait inherited from the same ancestral source, we have used cluster analysis to divide 132 breeds of dog into five primary breed groups.
    [Show full text]
  • Supplementary Materials
    Supplementary materials Supplementary Table S1: MGNC compound library Ingredien Molecule Caco- Mol ID MW AlogP OB (%) BBB DL FASA- HL t Name Name 2 shengdi MOL012254 campesterol 400.8 7.63 37.58 1.34 0.98 0.7 0.21 20.2 shengdi MOL000519 coniferin 314.4 3.16 31.11 0.42 -0.2 0.3 0.27 74.6 beta- shengdi MOL000359 414.8 8.08 36.91 1.32 0.99 0.8 0.23 20.2 sitosterol pachymic shengdi MOL000289 528.9 6.54 33.63 0.1 -0.6 0.8 0 9.27 acid Poricoic acid shengdi MOL000291 484.7 5.64 30.52 -0.08 -0.9 0.8 0 8.67 B Chrysanthem shengdi MOL004492 585 8.24 38.72 0.51 -1 0.6 0.3 17.5 axanthin 20- shengdi MOL011455 Hexadecano 418.6 1.91 32.7 -0.24 -0.4 0.7 0.29 104 ylingenol huanglian MOL001454 berberine 336.4 3.45 36.86 1.24 0.57 0.8 0.19 6.57 huanglian MOL013352 Obacunone 454.6 2.68 43.29 0.01 -0.4 0.8 0.31 -13 huanglian MOL002894 berberrubine 322.4 3.2 35.74 1.07 0.17 0.7 0.24 6.46 huanglian MOL002897 epiberberine 336.4 3.45 43.09 1.17 0.4 0.8 0.19 6.1 huanglian MOL002903 (R)-Canadine 339.4 3.4 55.37 1.04 0.57 0.8 0.2 6.41 huanglian MOL002904 Berlambine 351.4 2.49 36.68 0.97 0.17 0.8 0.28 7.33 Corchorosid huanglian MOL002907 404.6 1.34 105 -0.91 -1.3 0.8 0.29 6.68 e A_qt Magnogrand huanglian MOL000622 266.4 1.18 63.71 0.02 -0.2 0.2 0.3 3.17 iolide huanglian MOL000762 Palmidin A 510.5 4.52 35.36 -0.38 -1.5 0.7 0.39 33.2 huanglian MOL000785 palmatine 352.4 3.65 64.6 1.33 0.37 0.7 0.13 2.25 huanglian MOL000098 quercetin 302.3 1.5 46.43 0.05 -0.8 0.3 0.38 14.4 huanglian MOL001458 coptisine 320.3 3.25 30.67 1.21 0.32 0.9 0.26 9.33 huanglian MOL002668 Worenine
    [Show full text]
  • CDK5 Functions As a Tumor Promoter in Human Lung Cancer Jie Zeng1#, Shuanshuan Xie1#, Yang Liu1, Changxing Shen1, Xiaolian Song1, Guo-Lei Zhou2, 3, Changhui Wang1
    Journal of Cancer 2018, Vol. 9 3950 Ivyspring International Publisher Journal of Cancer 2018; 9(21): 3950-3961. doi: 10.7150/jca.25967 Research Paper CDK5 Functions as a Tumor Promoter in Human Lung Cancer Jie Zeng1#, Shuanshuan Xie1#, Yang Liu1, Changxing Shen1, Xiaolian Song1, Guo-Lei Zhou2, 3, Changhui Wang1 1. Department of Respiratory Medicine, Shanghai Tenth People’s Hospital, Tongji University, Shanghai 200072, PR China; 2. Department of Biological Sciences, Arkansas State University, State University, AR 72467, USA; 3. Molecular Biosciences Program, Arkansas State University, State University, AR 72467, USA. # These authors have contributed equally to this work. Corresponding author: Changhui Wang, No.301, Mid Yanchang Rd, Department of Respiratory Medicine, Shanghai Tenth People’s Hospital, Tongji University, Shanghai, China, 200072. Email: [email protected], Fax number: 86-021-66301685, Telephone: 86-021-66301685 © Ivyspring International Publisher. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions. Received: 2018.03.09; Accepted: 2018.08.19; Published: 2018.10.10 Abstract Cyclin-dependent kinase 5 (CDK5), an atypical member of the cyclin-dependent kinase family, plays an important role in the nervous system. Recent studies have shown that CDK5 is also associated with tumors. However, few studies have been done to investigate the mechanism underlying the connection between CDK5 and cancers. To explore the role of CDK5 in cancers by using an extensive bioinformatics data mining process. We mined the transcriptional, survival, functions and structure of CDK5 gene through databases and in vitro experiments.
    [Show full text]
  • RNA Sequencing Reveals a Diverse and Dynamic Repertoire of the Xenopus Tropicalis Transcriptome Over Development
    Downloaded from genome.cshlp.org on October 6, 2021 - Published by Cold Spring Harbor Laboratory Press Resource RNA sequencing reveals a diverse and dynamic repertoire of the Xenopus tropicalis transcriptome over development Meng How Tan,1,6,7 Kin Fai Au,2,6 Arielle L. Yablonovitch,1,3,6 Andrea E. Wills,1 Jason Chuang,4 Julie C. Baker,1 Wing Hung Wong,2,5 and Jin Billy Li1,7 1Department of Genetics, Stanford University School of Medicine, Stanford, California 94305, USA; 2Department of Statistics, School of Humanities and Sciences, Stanford University, Stanford, California 94305, USA; 3Program in Biophysics, School of Humanities and Sciences, Stanford University, Stanford, California 94305, USA; 4Department of Computer Science, School of Engineering, Stanford University, Stanford, California 94305, USA; 5Department of Health Research and Policy, Stanford University School of Medicine, Stanford, California 94305, USA The Xenopus embryo has provided key insights into fate specification, the cell cycle, and other fundamental developmental and cellular processes, yet a comprehensive understanding of its transcriptome is lacking. Here, we used paired end RNA sequencing (RNA-seq) to explore the transcriptome of Xenopus tropicalis in 23 distinct developmental stages. We determined expression levels of all genes annotated in RefSeq and Ensembl and showed for the first time on a genome-wide scale that, despite a general state of transcriptional silence in the earliest stages of development, approximately 150 genes are tran- scribed prior to the midblastula transition. In addition, our splicing analysis uncovered more than 10,000 novel splice junctions at each stage and revealed that many known genes have additional unannotated isoforms.
    [Show full text]
  • PARP Inhibition Suppresses GR–MYCN–CDK5– RB1–E2F1
    Published OnlineFirst August 22, 2019; DOI: 10.1158/1078-0432.CCR-19-0317 Translational Cancer Mechanisms and Therapy Clinical Cancer Research PARP Inhibition Suppresses GR–MYCN–CDK5– RB1–E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer Bo Liu1, Likun Li1, Guang Yang1, Chuandong Geng1, Yong Luo1, Wenhui Wu2, Ganiraju C. Manyam2, Dimitrios Korentzelos1, Sanghee Park1, Zhe Tang1, Cheng Wu1, Zhenyang Dong1, Michael Sigouros3, Andrea Sboner4,5,6, Himisha Beltran7, Yu Chen3,8,9, Paul G. Corn1, Michael T. Tetzlaff10, Patricia Troncoso10, Bradley Broom2, and Timothy C. Thompson1 Abstract Purpose: In this study, we addressed the underlying ing pathway that drives NED in prostatic adenocarcinoma mechanisms for the association between enzalutamide (ENZ) PDX and cell line models. Mechanistically, long-term treatment and neuroendocrine prostate cancer (NEPC), and ENZ treatment transcriptionally upregulates signaling of the critical involvement of MYCN, and loss of RB1 function in the GR–MYCN axis, leading to CDK5R1 and CDK5R2 upre- neuroendocrine differentiation (NED) of prostatic epithelial gulation, Rb1 phosphorylation, and N-Myc–mediated cells, and the development of NEPC. We further sought to and E2F1-mediated NED gene expression. Importantly, determine whether PARP inhibition could suppress NEPC, olaparib (OLA) or talazoparib (TALA) suppressed these and to identify molecular determinants of this therapeutic activities, and the combination of OLA and dinaciclib activity. (DINA), an inhibitor of CDK2 and CDK5, which also Experimental Design: We used a novel prostate cancer inhibits Rb1 phosphorylation, suppressed NED and signif- patient–derived xenograft (PDX) treatment model, prostatic icantly improved therapeutic efficiency in NEPC cells in vitro adenocarcinoma and NEPC cell lines, an NEPC organoid line, and in NEPC tumors in vivo.
    [Show full text]
  • Deciphering the Molecular Profile of Plaques, Memory Decline And
    ORIGINAL RESEARCH ARTICLE published: 16 April 2014 AGING NEUROSCIENCE doi: 10.3389/fnagi.2014.00075 Deciphering the molecular profile of plaques, memory decline and neuron loss in two mouse models for Alzheimer’s disease by deep sequencing Yvonne Bouter 1†,Tim Kacprowski 2,3†, Robert Weissmann4, Katharina Dietrich1, Henning Borgers 1, Andreas Brauß1, Christian Sperling 4, Oliver Wirths 1, Mario Albrecht 2,5, Lars R. Jensen4, Andreas W. Kuss 4* andThomas A. Bayer 1* 1 Division of Molecular Psychiatry, Georg-August-University Goettingen, University Medicine Goettingen, Goettingen, Germany 2 Department of Bioinformatics, Institute of Biometrics and Medical Informatics, University Medicine Greifswald, Greifswald, Germany 3 Department of Functional Genomics, Interfaculty Institute for Genetics and Functional Genomics, University Medicine Greifswald, Greifswald, Germany 4 Human Molecular Genetics, Department for Human Genetics of the Institute for Genetics and Functional Genomics, Institute for Human Genetics, University Medicine Greifswald, Ernst-Moritz-Arndt University Greifswald, Greifswald, Germany 5 Institute for Knowledge Discovery, Graz University of Technology, Graz, Austria Edited by: One of the central research questions on the etiology of Alzheimer’s disease (AD) is the Isidro Ferrer, University of Barcelona, elucidation of the molecular signatures triggered by the amyloid cascade of pathological Spain events. Next-generation sequencing allows the identification of genes involved in disease Reviewed by: Isidro Ferrer, University of Barcelona, processes in an unbiased manner. We have combined this technique with the analysis of Spain two AD mouse models: (1) The 5XFAD model develops early plaque formation, intraneu- Dietmar R. Thal, University of Ulm, ronal Ab aggregation, neuron loss, and behavioral deficits. (2)TheTg4–42 model expresses Germany N-truncated Ab4–42 and develops neuron loss and behavioral deficits albeit without plaque *Correspondence: formation.
    [Show full text]
  • UC San Francisco Previously Published Works
    UCSF UC San Francisco Previously Published Works Title FitSNPs: highly differentially expressed genes are more likely to have variants associated with disease. Permalink https://escholarship.org/uc/item/91k8p2km Journal Genome biology, 9(12) ISSN 1474-7596 Authors Chen, Rong Morgan, Alex A Dudley, Joel et al. Publication Date 2008 DOI 10.1186/gb-2008-9-12-r170 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Open Access Research2008ChenetVolume al. 9, Issue 12, Article R170 FitSNPs: highly differentially expressed genes are more likely to have variants associated with disease Rong Chen*†‡, Alex A Morgan*†‡, Joel Dudley*†‡, Tarangini Deshpande§, Li Li†, Keiichi Kodama*†‡, Annie P Chiang*†‡ and Atul J Butte*†‡ Addresses: *Stanford Center for Biomedical Informatics Research, 251 Cmpus Drive, Stanford, CA 94305, USA. †Department of Pediatrics, Stanford University School of Medicine, Stanford, CA 94305, USA. ‡Lucile Packard Children's Hospital, 725 Welch Road, Palo Alto, CA 94304, USA. §NuMedii Inc., Menlo Park, CA 94025, USA. Correspondence: Atul J Butte. Email: [email protected] Published: 5 December 2008 Received: 17 June 2008 Revised: 26 September 2008 Genome Biology 2008, 9:R170 (doi:10.1186/gb-2008-9-12-r170) Accepted: 5 December 2008 The electronic version of this article is the complete one and can be found online at http://genomebiology.com/2008/9/12/R170 © 2008 Chen et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
    [Show full text]
  • Identification and Analysis of the Mouse Basic/Helix-Loop-Helix
    中国科技论文在线 http://www.paper.edu.cn BBRC Biochemical and Biophysical Research Communications 350 (2006) 648–656 www.elsevier.com/locate/ybbrc Identification and analysis of the mouse basic/Helix-Loop-Helix transcription factor family Jing Li a,b, Qi Liu b, Mengsheng Qiu c, Yuchun Pan a,*, Yixue Li d,*, Tieliu Shi d,e,* a School of Agriculture and Biology, Shanghai Jiao Tong University, Shanghai 201101, China b School of Life Science and Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, China c Department of Anatomical Sciences and Neurobiology, School of Medicine, University of Louisville, Louisville, KY 40292, USA d Bioinformatics Center, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, China e Bioinformation Center, Shanghai University, Shanghai 200444, China Received 23 August 2006 Available online 29 September 2006 Abstract The basic/Helix-Loop-Helix (bHLH) proteins are a family of transcription factors that regulates a variety of biological processes. Based on a previously defined consensus motif, we identified the complete set of bHLH protein family from the mouse proteome dat- abases and carried out a series of bioinformatics analysis. As results, 124 mouse bHLH proteins were identified in this study, and 28 of them were additional bHLH proteins beyond the previous report. These 124 mouse bHLH proteins were classified into groups from A to F by the nomenclature and phylogenetic analysis. Statistic analysis of the Gene Ontology annotation of these proteins showed that the bHLH proteins tend to perform functions related to cell differentiation and development. Gene function enrichmeznt analysis among six groups illuminated that the proteins in certain group tend to have special biology functions, so that the molecular function of the unchar- acterized proteins in groups could be inferred.
    [Show full text]
  • 1 Novel Expression Signatures Identified by Transcriptional Analysis
    ARD Online First, published on October 7, 2009 as 10.1136/ard.2009.108043 Ann Rheum Dis: first published as 10.1136/ard.2009.108043 on 7 October 2009. Downloaded from Novel expression signatures identified by transcriptional analysis of separated leukocyte subsets in SLE and vasculitis 1Paul A Lyons, 1Eoin F McKinney, 1Tim F Rayner, 1Alexander Hatton, 1Hayley B Woffendin, 1Maria Koukoulaki, 2Thomas C Freeman, 1David RW Jayne, 1Afzal N Chaudhry, and 1Kenneth GC Smith. 1Cambridge Institute for Medical Research and Department of Medicine, Addenbrooke’s Hospital, Hills Road, Cambridge, CB2 0XY, UK 2Roslin Institute, University of Edinburgh, Roslin, Midlothian, EH25 9PS, UK Correspondence should be addressed to Dr Paul Lyons or Prof Kenneth Smith, Department of Medicine, Cambridge Institute for Medical Research, Addenbrooke’s Hospital, Hills Road, Cambridge, CB2 0XY, UK. Telephone: +44 1223 762642, Fax: +44 1223 762640, E-mail: [email protected] or [email protected] Key words: Gene expression, autoimmune disease, SLE, vasculitis Word count: 2,906 The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non-exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd and its Licensees to permit this article (if accepted) to be published in Annals of the Rheumatic Diseases and any other BMJPGL products to exploit all subsidiary rights, as set out in their licence (http://ard.bmj.com/ifora/licence.pdf). http://ard.bmj.com/ on September 29, 2021 by guest. Protected copyright. 1 Copyright Article author (or their employer) 2009.
    [Show full text]
  • CDK5R2(P39) Antibody (N-Term) Blocking Peptide Synthetic Peptide Catalog # Bp7742a
    10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 CDK5R2(p39) Antibody (N-term) Blocking Peptide Synthetic peptide Catalog # BP7742a Specification CDK5R2(p39) Antibody (N-term) Blocking CDK5R2(p39) Antibody (N-term) Blocking Peptide Peptide - Background - Product Information CDK5R2(p39) is a neuron-specific activator of Primary Accession Q13319 CDK5 kinase. It associates with CDK5 to form an active kinase. This protein and neuron-specific CDK5 activator CDK5R2(p39) Antibody (N-term) Blocking Peptide - Additional Information CDK5R1/p39NCK5A both share limited similarity to cyclins, and thus may define a distinct family of cyclin-dependent kinase Gene ID 8941 activating proteins. Other Names CDK5R2(p39) Antibody (N-term) Blocking Cyclin-dependent kinase 5 activator 2, Peptide - References CDK5 activator 2, Cyclin-dependent kinase 5 regulatory subunit 2, p39, p39I, CDK5R2, Rademakers,R., Neurobiol. Aging 26 (8), NCK5AI 1145-1151 (2005)Dhavan,R., J. Neurosci. 22 Target/Specificity (18), 7879-7891 (2002)Patzke,H., J. Biol. Chem. The synthetic peptide sequence used to 277 (10), 8054-8060 (2002) generate the antibody <a href=/products/AP7742a>AP7742a</a> was selected from the p39 region of human CDK5R2(p39). A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. Format Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. Precautions This product is for research use only.
    [Show full text]
  • Cis-Regulatory Chromatin Contacts in Neural Cells Reveal Contributions
    bioRxiv preprint doi: https://doi.org/10.1101/494450; this version posted February 22, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 cis-Regulatory Chromatin Contacts in Neural Cells Reveal Contributions of Genetic Variants to 2 Complex Neurological Disorders 3 4 5 Authors: Michael Song1,2, Xiaoyu Yang1, Xingjie Ren1, Lenka Maliskova1, Bingkun Li1, Ian Jones1, 6 Chao Wang3, Fadi Jacob4,5, Kenneth Wu6, Michela Traglia7, Tsz Wai Tam1, Kirsty Jamieson1, Si-Yao 7 Lu8, Guo-Li Ming4,9,10,11, Jun Yao8, Lauren A. Weiss1,7, Jesse Dixon12, Luke M. Judge6,13, Bruce R 8 Conklin6,14, Hongjun Song4,9,10,15, Li Gan3, Yin Shen1,2,16* 9 10 11 Affiliation: 12 13 1Institute for Human Genetics, University of California, San Francisco, San Francisco, CA, USA 14 2Pharmaceutical Sciences and Pharmacogenomics Graduate Program, University of California, San 15 Francisco, San Francisco, CA, USA 16 3Gladstone Institute for Neurological Disorders, San Francisco, CA, USA 17 4Department of Neuroscience and Mahoney Institute for Neurosciences, Perelman School for Medicine, 18 University of Pennsylvania, Philadelphia, PA 19104, USA. 19 5The Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, 20 Baltimore, MD 21205, USA. 21 6Gladstone Institute for Cardiovascular Disease, San Francisco, CA, USA 22 7Department of Psychiatry, University of California, San Francisco, San Francisco, CA, USA 23 8State Key Laboratory of Membrane Biology, Tsinghua-Peking Center for Life Sciences, School of Life 24 Sciences, Tsinghua University, Beijing, China.
    [Show full text]